JP2014139229A5 - - Google Patents

Download PDF

Info

Publication number
JP2014139229A5
JP2014139229A5 JP2014075596A JP2014075596A JP2014139229A5 JP 2014139229 A5 JP2014139229 A5 JP 2014139229A5 JP 2014075596 A JP2014075596 A JP 2014075596A JP 2014075596 A JP2014075596 A JP 2014075596A JP 2014139229 A5 JP2014139229 A5 JP 2014139229A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
botulinum toxin
monosaccharide
trisaccharide
disaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014075596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014139229A (ja
Filing date
Publication date
Priority claimed from US11/524,683 external-priority patent/US8137677B2/en
Application filed filed Critical
Publication of JP2014139229A publication Critical patent/JP2014139229A/ja
Publication of JP2014139229A5 publication Critical patent/JP2014139229A5/ja
Pending legal-status Critical Current

Links

JP2014075596A 2005-10-06 2014-04-01 非タンパク質安定化クロストリジウム毒素医薬組成物 Pending JP2014139229A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72512605P 2005-10-06 2005-10-06
US60/725,126 2005-10-06
US11/524,683 2006-09-21
US11/524,683 US8137677B2 (en) 2005-10-06 2006-09-21 Non-protein stabilized clostridial toxin pharmaceutical compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012162277A Division JP5758856B2 (ja) 2005-10-06 2012-07-23 非タンパク質安定化クロストリジウム毒素医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017010322A Division JP6235176B2 (ja) 2005-10-06 2017-01-24 非タンパク質安定化クロストリジウム毒素医薬組成物

Publications (2)

Publication Number Publication Date
JP2014139229A JP2014139229A (ja) 2014-07-31
JP2014139229A5 true JP2014139229A5 (enExample) 2015-04-23

Family

ID=37527018

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008534672A Expired - Fee Related JP5140595B2 (ja) 2005-10-06 2006-10-04 非タンパク質安定化クロストリジウム毒素医薬組成物
JP2012162277A Expired - Fee Related JP5758856B2 (ja) 2005-10-06 2012-07-23 非タンパク質安定化クロストリジウム毒素医薬組成物
JP2014075596A Pending JP2014139229A (ja) 2005-10-06 2014-04-01 非タンパク質安定化クロストリジウム毒素医薬組成物
JP2017010322A Expired - Fee Related JP6235176B2 (ja) 2005-10-06 2017-01-24 非タンパク質安定化クロストリジウム毒素医薬組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2008534672A Expired - Fee Related JP5140595B2 (ja) 2005-10-06 2006-10-04 非タンパク質安定化クロストリジウム毒素医薬組成物
JP2012162277A Expired - Fee Related JP5758856B2 (ja) 2005-10-06 2012-07-23 非タンパク質安定化クロストリジウム毒素医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017010322A Expired - Fee Related JP6235176B2 (ja) 2005-10-06 2017-01-24 非タンパク質安定化クロストリジウム毒素医薬組成物

Country Status (16)

Country Link
US (5) US8137677B2 (enExample)
EP (2) EP2679217B1 (enExample)
JP (4) JP5140595B2 (enExample)
KR (1) KR101314952B1 (enExample)
AU (1) AU2006299366B2 (enExample)
CA (1) CA2602926C (enExample)
CY (1) CY1117727T1 (enExample)
DK (1) DK2679217T3 (enExample)
ES (1) ES2580010T3 (enExample)
HU (1) HUE027810T2 (enExample)
MX (1) MX2007012062A (enExample)
NZ (1) NZ562033A (enExample)
PL (1) PL2679217T3 (enExample)
PT (1) PT2679217T (enExample)
SI (1) SI2679217T1 (enExample)
WO (1) WO2007041664A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150570A1 (en) * 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
KR100852824B1 (ko) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
WO2006094263A2 (en) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
KR20130079645A (ko) 2005-07-18 2013-07-10 유니버시티 오브 메사츄세츠 로웰 나노에멀젼 조성물 및 이의 제조 및 사용 방법
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
CN101374498A (zh) 2005-12-01 2009-02-25 麻萨诸塞州洛厄尔大学 肉毒杆菌纳米乳液
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
SG10201607909WA (en) 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
US8617568B2 (en) * 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
EP2198007B1 (en) 2007-09-14 2017-10-25 Sanofi Pasteur Biologics, LLC Pharmaceutical compositions containing clostridium difficile toxoids a and b
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
RU2535003C2 (ru) * 2008-12-10 2014-12-10 Аллерган, Инк. Фармацевтические композиции токсина клостридий
ES2669020T3 (es) 2008-12-31 2018-05-23 Revance Therapeutics, Inc. Formulaciones inyectables de toxina botulínica
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
ES2615281T3 (es) 2009-06-24 2017-06-06 Charles N.S. Soparkar Suplementación con cinc para aumentar la capacidad de respuesta al tratamiento con metaloproteasa
JP6043627B2 (ja) 2009-06-25 2016-12-14 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． アルブミン非含有ボツリヌス毒素製剤
EP2504878A4 (en) * 2009-11-09 2014-01-08 Enerdel Inc SCALABLE BATTERY MODULE
AU2011316111B2 (en) * 2010-10-12 2015-05-28 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
ES2636680T5 (es) * 2011-03-31 2023-10-31 Medy Tox Inc Preparación liofilizada de toxina botulínica
KR20140147950A (ko) * 2013-06-20 2014-12-31 서울대학교산학협력단 필러와 보틀리눔 독소를 포함하는 피부 주름, 노화 개선 또는 신경근육 관련 질환 치료용 조성물
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
TWI688392B (zh) 2014-07-07 2020-03-21 美商救生筏生物科技公司 無長循環材料之泊洛沙姆組成物以及其製造方法和用途
RU2694820C9 (ru) 2014-12-23 2019-08-12 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
WO2017179775A1 (en) * 2016-04-12 2017-10-19 Hugel Inc. Microstructure formulation techniques for botulinum toxin
IL265109B2 (en) * 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3470054B1 (en) * 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
BR112020012641A2 (pt) 2017-12-20 2020-12-01 Allergan, Inc. polipeptídeos de domínio de ligação celular de toxina de botulinum e métodos de uso para rejuvenescimento da pele
MX2021002992A (es) * 2018-09-13 2021-11-12 Allergan Inc Composiciones de toxina clostridial y acido hialuronico.

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
DE3603444A1 (de) * 1986-02-05 1987-08-06 Thomae Gmbh Dr K Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
WO1994000481A1 (en) 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
ES2198484T3 (es) 1995-06-06 2004-02-01 L. Bruce Pearce Composiciones y procedimientos mejorados para quimiodenervacion usando neurotoxinas.
JPH0952844A (ja) * 1995-08-10 1997-02-25 Amano Pharmaceut Co Ltd 酵素含有内服液剤
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
CN1073626C (zh) 1997-10-18 2001-10-24 卫生部兰州生物制品研究所 A型肉毒结晶毒素的生产工艺及生产该毒素所需的冻干保护液
AU2340299A (en) * 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
IL126182A0 (en) 1998-09-11 1999-05-09 Nun Yehoshua Ben Cryosurgical instrument
US20050147690A1 (en) * 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
JP2003522154A (ja) 2000-02-08 2003-07-22 アラーガン、インコーポレイテッド ボツリヌス毒素医薬組成物
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
BRPI0311959B8 (pt) * 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
US20040143213A1 (en) * 2002-11-12 2004-07-22 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
ATE426408T1 (de) 2002-12-20 2009-04-15 Botulinum Toxin Res Ass Inc Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin
WO2004093870A1 (en) * 2003-03-20 2004-11-04 Pharmacia Corporation Treatment and prevention of otic disorders
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US8153591B2 (en) * 2003-08-26 2012-04-10 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
WO2005055945A2 (en) * 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US20050214325A1 (en) * 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
KR101352299B1 (ko) * 2004-06-28 2014-02-17 벨로시스 파마슈티컬스 에이/에스 액상 제형용 담체로서의 다공성 정제
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
KR100852824B1 (ko) * 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
ES2526912T3 (es) * 2004-08-04 2015-01-16 Ipsen Biopharm Limited Composición farmacéutica que contiene neurotoxina botulínica A2
DK1797109T3 (en) * 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
CA2598204C (en) * 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
ATE523207T1 (de) * 2005-09-16 2011-09-15 Merial Ltd Stabilisatoren für gefriergetrocknete impfstoffe
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
EP2829282B1 (en) * 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2525777B1 (en) * 2010-01-20 2019-05-29 UroGen Pharma Ltd. Material and method for treating internal cavities
AU2011316111B2 (en) * 2010-10-12 2015-05-28 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients

Similar Documents

Publication Publication Date Title
EP4360652A3 (en) Adeno-associated virus formulations
JP2014129360A5 (enExample)
CL2018003178A1 (es) Composición farmacéutica
EP3928800A3 (en) Dry powder composition comprising long-chain rna
IL308091A (en) Stabilized Clostridium toxin preparations without protein
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
RU2013148119A (ru) Лиофилизированный препарат ботулотоксина
HRP20201242T1 (hr) Tekući farmaceutski pripravak
HRP20210749T1 (hr) Farmaceutski pripravci koji sadrže azd9291
WO2017100700A3 (en) Peptides for renal therapy
WO2015082570A8 (en) Cmv vaccines
JP2016535065A5 (enExample)
JP2015134763A5 (enExample)
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
HK1247856A1 (zh) 羟丙基β-环糊精组合物及方法
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
WO2017083266A8 (en) Novel formulations
CY1125375T1 (el) Ενα λυοφιλοποιημενο φαρμακευτικο σκευασμα και η χρηση του
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
BR112021004771A2 (pt) Composições de ácido hialurônico-toxina clostridial
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
JP2016510747A5 (enExample)
JP2016534062A5 (enExample)
WO2015149016A3 (en) Breast and ovarian cancer vaccines